UBS Maintains Buy on CymaBay Therapeutics, Raises Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Eliana Merle maintains a Buy rating on CymaBay Therapeutics (NASDAQ:CBAY) and raises the price target from $18 to $25.
September 26, 2023 | 2:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS analyst maintains a Buy rating on CymaBay Therapeutics and raises the price target from $18 to $25.
The news of UBS maintaining a Buy rating and raising the price target for CymaBay Therapeutics is directly related to the company and is likely to have a positive impact on its stock price in the short term. Investors may see this as a sign of confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100